Wellington Management Group LLP Sells 15,905 Shares of Monopar Therapeutics Inc. $MNPR

Wellington Management Group LLP trimmed its position in Monopar Therapeutics Inc. (NASDAQ:MNPR) by 9.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 158,437 shares of the company’s stock after selling 15,905 shares during the quarter. Wellington Management Group LLP owned 2.36% of Monopar Therapeutics worth $14,670,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new stake in shares of Monopar Therapeutics in the third quarter valued at about $28,000. BNP Paribas Financial Markets grew its holdings in Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Monopar Therapeutics during the 4th quarter worth about $65,000. Caitong International Asset Management Co. Ltd purchased a new position in Monopar Therapeutics during the 4th quarter valued at about $86,000. Finally, JPMorgan Chase & Co. increased its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the period. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Insider Buying and Selling at Monopar Therapeutics

In related news, Director Kim Tsuchimoto sold 4,090 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total transaction of $455,585.10. Following the transaction, the director directly owned 7,396 shares of the company’s stock, valued at $823,840.44. This represents a 35.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the sale, the director owned 23,751 shares of the company’s stock, valued at approximately $2,654,649.27. This trade represents a 11.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is owned by insiders.

Monopar Therapeutics Price Performance

Shares of Monopar Therapeutics stock opened at $117.56 on Tuesday. The company has a market cap of $788.83 million, a P/E ratio of -54.17 and a beta of 1.49. The firm’s 50 day moving average price is $110.24 and its 200-day moving average price is $77.64. Monopar Therapeutics Inc. has a 52-week low of $38.66 and a 52-week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.02. As a group, equities research analysts forecast that Monopar Therapeutics Inc. will post -2.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on MNPR shares. Barclays reaffirmed an “overweight” rating and issued a $128.00 price target (up from $125.00) on shares of Monopar Therapeutics in a research report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Zacks Research cut Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Finally, Wall Street Zen lowered Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $118.67.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.